Otarmeni™ (lunsotogene parvec-cwha) Approved by FDA as First and Only Gene Therapy for Genetic Hearing Loss; Regeneron to Provide Otarmeni for Free in the U.S.

Approval in severe-to-profound and profound OTOF -related hearing loss is based on pivotal results of the CHORD trial demonstrating 80% of ...

Book ban battles pivot as challenges to more titles come from outside groups

Book challenges neared a record high in 2025, showing an increase in pressure from political groups and officials as opposed ...